Hopes rise that Morphic might have cracked the conundrum of oral integrin inhibitors.
Data from Israel’s real-world experience with Pfizer/Biontech’s Covid-19 vaccine should silence any doubters.
FDA briefing documents show intriguing findings on asymptomatic prevention, though these are based on small numbers.
Early data could give clues about whether gene therapies from Sio, Passage Bio or Lysogene will come out on top in this rare inherited disease.
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
The Parp inhibitor registers an unexpected clinical win in the adjuvant setting, but more convincing data might still be needed.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?